BioWorld

May 12, 2010

Jazz Repaying Debt Ahead of Fibromyalgia Drug Decision

Jazz Pharmaceuticals Inc. is raising about $58.5 million in a public offering to pay off a sizeable chunk of its outstanding debt ahead of an FDA decision on fibromyalgia drug JZP-6 (sodium oxybate), expected this fall. (BioWorld Today) Read More

Galapagos Keeps Them Coming Back; Roche Widens COPD Deal

Different Stem Cell Types Have Critical Difference in Fragile X

Amorfix, Epitomics Partnering on Cancer Antibody Targets

Other News To Note

Stock Movers

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...